Endocrine Oncology (Jan 2023)

Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes

  • Christie G Turin,
  • Molly M Crenshaw,
  • Lauren Fishbein

DOI
https://doi.org/10.1530/EO-22-0044
Journal volume & issue
Vol. 2, no. 1
pp. R65 – R77

Abstract

Read online

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors arising from the adrenal medulla and extra-adrenal ganglia, respectively. Approximately 15–25% of PCC/PGL can become metastatic. Up to 30–40% of patients with PCC/PGL have a germline pathogenic variant in a known susceptibility gene for PCC/PGL; therefore, all patients with PCC/PGL should undergo clinical genetic testing. Most of the susceptibility genes are associated with variable penetrance for PCC/PGL and are associated with different syndromes, which include susceptibility for other tumors and conditions. The objective of this review is to provide an overview of the germline susceptibility genes for PCC/PGL, the associated clinical syndromes, and recommended surveillance.

Keywords